Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia.
Charlotte Ann BradburyJulie PellQuentin HillCatherine BagotNichola CooperJenny IngramKatie BrehenyRebecca KandiyaliRachel RaymentGillian EvansKate TalksIan ThomasRosemary GreenwoodPublished in: The New England journal of medicine (2021)
The addition of mycophenolate mofetil to a glucocorticoid for first-line treatment of immune thrombocytopenia resulted in greater response and a lower risk of refractory or relapsed immune thrombocytopenia, but with somewhat decreased quality of life. (Funded by the U.K. National Institute for Health Research; FLIGHT ClinicalTrials.gov number, NCT03156452; EudraCT number, 2017-001171-23.).